Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of mouse FACS-purified cortical projection neurons using Affymetrix 430 2.0 microarrays
3 subtypes of cortical projection neurons were purified by fluorescence-activated cell sorting (FACS) at 4 different stages of development from mouse cortex. A detailed description of the data set is described in Arlotta, P et al (2005) and Molyneaux, BJ et al (2009). The hybridization cocktails use...
ORGANISM(S): Mus musculus 
2009-10-09 | E-GEOD-17783 | biostudies-arrayexpress
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

Methods

In an open-label, ad...
S-EPMC8362592 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
S-EPMC8362594 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.

Objective

To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.

Design, setting, and participants

The ongoing...
S-EPMC8491132 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain.

Objective

To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19.

Design, setting, and participants

In an ongoing adaptive platfor...
S-EPMC8941448 | biostudies-literature
UnknownInterleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

Background

The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-...
S-EPMC7953461 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Importance

Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.

Objective

To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patien...
S-EPMC10326520 | biostudies-literature
UnknownLopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.

Purpose

To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).

Methods

Critically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloroquine, combination therapy of lopin...
S-EPMC8274471 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Importance

The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.

Objective

To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.

Design, setting, and participants

S-EPMC9857594 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.

Background

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no stati...
S-EPMC10755839 | biostudies-literature
Sort   by:  
 Page size